Single User License
INR 101130
Site License
INR 202260
Corporate User License
INR 303390

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Rigel Pharmaceuticals, Inc.-Product Pipeline Review-2015

Rigel Pharmaceuticals, Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Rigel Pharmaceuticals, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Rigel Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Rigel Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rigel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Rigel Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Rigel Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Rigel Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Rigel Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Rigel Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Rigel Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Rigel Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rigel Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Rigel Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Rigel Pharmaceuticals, Inc. Snapshot 5

Rigel Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Rigel Pharmaceuticals, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Rigel Pharmaceuticals, Inc.-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Rigel Pharmaceuticals, Inc.-Pipeline Products Glance 14

Rigel Pharmaceuticals, Inc.-Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Rigel Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Rigel Pharmaceuticals, Inc.-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Rigel Pharmaceuticals, Inc.-Drug Profiles 17

fostamatinib disodium 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

R-348 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Small Molecule to Inhibit Growth and Differentiation Factor 8 for Ventilator Atrophy 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecules to Antagonize TGF Beta Receptor for Cancer 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Rigel Pharmaceuticals, Inc.-Pipeline Analysis 24

Rigel Pharmaceuticals, Inc.-Pipeline Products by Target 24

Rigel Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 25

Rigel Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 26

Rigel Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 27

Rigel Pharmaceuticals, Inc.-Recent Pipeline Updates 28

Rigel Pharmaceuticals, Inc.-Dormant Projects 31

Rigel Pharmaceuticals, Inc.-Discontinued Pipeline Products 32

Discontinued Pipeline Product Profiles 32

fostamatinib disodium 32

R-333 32

R-548 32

Rigel Pharmaceuticals, Inc.-Company Statement 33

Rigel Pharmaceuticals, Inc.-Locations And Subsidiaries 36

Head Office 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

Rigel Pharmaceuticals, Inc., Key Information 5

Rigel Pharmaceuticals, Inc., Key Facts 5

Rigel Pharmaceuticals, Inc.-Pipeline by Indication, 2015 7

Rigel Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 8

Rigel Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 9

Rigel Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 10

Rigel Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 11

Rigel Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 12

Rigel Pharmaceuticals, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 13

Rigel Pharmaceuticals, Inc.-Phase III, 2015 14

Rigel Pharmaceuticals, Inc.-Phase II, 2015 15

Rigel Pharmaceuticals, Inc.-Preclinical, 2015 16

Rigel Pharmaceuticals, Inc.-Pipeline by Target, 2015 24

Rigel Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 25

Rigel Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 26

Rigel Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 27

Rigel Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 28

Rigel Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 31

Rigel Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 32

List of Figures

Rigel Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 6

Rigel Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 8

Rigel Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 9

Rigel Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 12

Rigel Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 24

Rigel Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 25

Rigel Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 26

Rigel Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Rigel Pharmaceuticals, Inc.; Rigel Pharmaceuticals, Inc. - Key Therapeutics; Rigel Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Rigel Pharmaceuticals, Inc. - News; Rigel Pharmaceuticals, Inc. - Latest Updates; Rigel Pharmaceuticals, Inc. - Pipeline; Rigel Pharmaceuticals, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com